These apCAFs subsequently recruit FOXP1+ regulatory T cells through PD-L2-RGMB interactions, contributing to neoadjuvant immunotherapy resistance in early-stage lung cancer [64]. This evidence concerns the gene PDCD1LG2 and lung cancer.